Loading…
Continue Reading
Related articles from the knowledge base
COMPARISON
Flow is for clinical depression. Pulsetto is for autonomic calm. Sychedelic is for cognitive performance. Here's how to pick the right one.
Loading…
Continue Reading
Related articles from the knowledge base
FREQUENTLY ASKED
Yes, within established parameters. The Bikson et al. (2016) safety review of over 33,200 tDCS sessions found no serious adverse events at currents ≤4 mA and durations ≤40 minutes. The most common side effect is mild tingling at the electrode site during the first 30–60 seconds. Sychedelic operates at 2.0 mA for 20 minutes — well inside that safety envelope.
Not directly. Vagus nerve stimulation modulates autonomic tone, which can indirectly improve sleep latency by reducing sympathetic arousal. But for focus, working memory, and DLPFC-mediated executive function, tDCS provides more targeted modulation.
Regulatory pathways differ by market. In the US, the FDA approved Flow FL-100 as a prescription medical device for Major Depressive Disorder in December 2025. In the UK and EU, the same device has been available since 2019 as a CE-marked medical device that consumers can purchase directly. Same hardware, different regulatory framework.
The published literature supports a minimum 24-hour gap between sessions. Long-term potentiation — the synaptic mechanism behind tDCS's cumulative effects — requires a consolidation window. Most clinical protocols use 3–5 sessions per week with rest days.
They aren't competitors in a strict sense. If you want cognitive performance, focus, and sleep optimisation, Sychedelic is mechanistically more targeted. If you want autonomic calm and stress reduction at the lowest entry price, Pulsetto is a reasonable starting point. Some users own both for different use cases.
In one of the only head-to-head studies, McIntire et al. (2017, PMID 28851554) found that 2 mA DLPFC tDCS sustained vigilance and working memory for 6 hours under sleep deprivation, outperforming caffeine on both performance and subjective mood measures. The mechanisms are entirely different: caffeine blocks adenosine receptors (masking fatigue); tDCS lowers neuronal firing thresholds (modifying capacity).
Yes. The device is battery-powered, generates no RF emissions during stimulation, and complies with TSA and IATA carry-on guidelines for battery-powered wearables. It should travel as carry-on, not checked baggage.
Yes. None of these devices should be used by people with metal cranial implants, cardiac pacemakers, implanted defibrillators, a history of epilepsy or seizures, active scalp or neck skin conditions, or during pregnancy. Always consult a physician before starting any neurostimulation device, particularly if you take medications that affect seizure threshold or cardiac rhythm.
THE INSTRUMENT
Sychedelic combines everything described in this article into one 20-minute protocol.